Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) show increased susceptibility to in vivo renal ischemia/reperfusion injury.

@article{Szakly2011MiceDI,
  title={Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) show increased susceptibility to in vivo renal ischemia/reperfusion injury.},
  author={P{\'e}ter Szak{\'a}ly and Eszter L{\'a}szl{\'o} and Krisztina Kov{\'a}cs and B{\'o}gl{\'a}rka R{\'a}cz and Gabriella Horvath and Andrea Ferencz and Andrea Lubics and P{\'e}ter Kiss and Andrea Tamas and R{\'e}ka Brubel and Balazs Opper and A. Ramesha Baba and Hitoshi Hashimoto and J{\'o}zsef Farkas and Attila Matkovits and Tam{\'a}s Magyarlaki and Zsuzsanna Helyes and Dora Reglodi},
  journal={Neuropeptides},
  year={2011},
  volume={45 2},
  pages={113-21}
}
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide with well-known cytoprotective effects. We have reported earlier that PACAP decreases mortality and the degree of tubular atrophy in a rat model of renal ischemia/reperfusion injury. Recently, we have shown that kidney cultures isolated from PACAP deficient mice show increased susceptibility to renal oxidative stress. Based on these previous studies, we raised the question whether PACAP deficient mice display increased… CONTINUE READING